1. Home
  2. LNN vs SLDB Comparison

LNN vs SLDB Comparison

Compare LNN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lindsay Corporation

LNN

Lindsay Corporation

N/A

Current Price

$115.09

Market Cap

1.1B

Sector

Industrials

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$48.95

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LNN
SLDB
Founded
1954
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
LNN
SLDB
Price
$115.09
$48.95
Analyst Decision
Hold
Strong Buy
Analyst Count
1
11
Target Price
$113.00
$16.36
AVG Volume (30 Days)
95.0K
878.6K
Earning Date
04-02-2026
05-12-2026
Dividend Yield
1.35%
N/A
EPS Growth
12.81
34.97
EPS
4.22
N/A
Revenue
$676,368,000.00
$8,094,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.74
N/A
P/E Ratio
$27.05
N/A
Revenue Growth
11.41
N/A
52 Week Low
$97.27
$3.79
52 Week High
$148.00
$11.45

Technical Indicators

Market Signals
Indicator
LNN
SLDB
Relative Strength Index (RSI) 55.02 56.51
Support Level $116.15 $5.21
Resistance Level $120.01 $11.45
Average True Range (ATR) 2.85 0.43
MACD 0.28 0.06
Stochastic Oscillator 62.89 67.25

Price Performance

Historical Comparison
LNN
SLDB

About LNN Lindsay Corporation

Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: